Prapela will commercialise medical devices for infants administering to fight drug withdrawal and cardiorespiratory problems.

Prapela, a US-based developer of medical devices for infants, officially launched out of Harvard University’s Wyss Institute for Biologically Inspired Engineering yesterday.

Founded in 2017, Prapela has secured a licence for medical devices that administer stochastic vibro-tactile stimulation (SVS), a non-pharmacological therapy that relies on vibrations to help infants overcome neonatal abstinence syndrome.

Neonatal abstinence syndrome, which causes drug withdrawal symptoms, can occur when the mother has been taking addictive drugs such as opioid painkillers during pregnancy, and can lead…